Zoetis Reports Flat Revenue Amid Companion Animal Market Pressures
Event summary
- Zoetis reported $2.5 billion in revenue for Q2 2026, flat year-over-year and down 1% organically.
- Companion animal sales fell 11% in the U.S. due to lower clinic visits and price sensitivity.
- Livestock sales grew 23% in the U.S., driven by cattle and poultry performance.
- International revenue increased 8%, led by parasiticides and diagnostics growth.
- Zoetis acquired VitalRADS, expanding its diagnostics capabilities.
The big picture
Zoetis faces a challenging environment in the companion animal segment, where macroeconomic factors and heightened competition are reducing demand. The company is countering this with targeted investments in innovation and business development, particularly in livestock and diagnostics. Zoetis' diversified portfolio and strong pipeline of potential blockbusters position it to navigate these pressures, but execution will be key.
What we're watching
- Market Adaptation
- How Zoetis will adjust its commercial strategy to address companion animal market pressures.
- Pipeline Progress
- The pace at which Zoetis advances its 12 potential blockbuster candidates in chronic diseases and oncology.
- Diagnostics Expansion
- Whether the VitalRADS acquisition will successfully integrate into Zoetis' diagnostics portfolio.
Related topics